DMK Pharmaceuticals Company Description
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases.
The company’s lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder.
Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose.
The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023.
The company is headquartered in San Diego, California. On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | United States |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 12 |
Contact Details
Address: 11682 El Camino Real San Diego, Delaware 92130 United States | |
| Phone | 858 997 2400 |
| Website | dmkpharmaceuticals.com |
Stock Details
| Ticker Symbol | DMKPQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US00547W3079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eddie Wabern Glover | Chief Executive Officer of US Compounding Inc |
| Seth Abraham Cohen | Chief Restructuring Officer |